# Ximing Ding

> Ximing Ding is a seed investor at Pureos Bioventures backing Oncology and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pureos Bioventures](https://shizune.co/investors/profile/pureos-bioventures)
- Total investments: 2
- Last investment: Oct 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ximing-ding-4b0b4851/

Ximing Ding is a seed investor at Pureos Bioventures focused on Oncology and Biotechnology. Ximing Ding

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Oncology | 1 | 50% |
| Biotechnology | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series A | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M | Series A | Oct 16, 2025 |  |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $32.2M | Seed | Jun 11, 2024 |  |

2 of 2 investments shown.

## Co-investors
- [Pontifax](https://shizune.co/investors/profile/pontifax) — VC Fund, 4 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Dawn Biopharma](https://shizune.co/investors/profile/dawn-biopharma) — VC Fund, 2 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 2 deals together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 1 deal together
- [Angelini Ventures](https://shizune.co/investors/profile/angelini-ventures) — VC Fund, 1 deal together

## About Pureos Bioventures

VC Fund · Küsnacht, Switzerland

Pureos Bioventures is a new venture capital fund located in Zurich to exclusively invest in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats

4 contacts available at Pureos Bioventures.

| Name | Title | Profile |
| --- | --- | --- |
| Klaus Breiner | Managing Partner & Founding partner | https://shizune.co/investors/profile/klaus-breiner |
| Martin Münchbach | Managing Partner & Founding Partner | https://shizune.co/investors/profile/martin-mnchbach |
| Dominik Escher | Managing Partner & Founding partner | https://shizune.co/investors/profile/dominik-escher |
| Ximing Ding | Investment Manager | https://shizune.co/investors/profile/ximing-ding-d13b |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Ximing Ding invest in?

Ximing Ding invests primarily in Oncology and Biotechnology startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ximing Ding last invest?

The most recent investment recorded for Ximing Ding closed in Oct 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co